Meitheal Entered into an Exclusive License Agreement with Tonghua Dongbao Pharmaceutical to Commercialize Three Insulin Biosimilars in the US
Shots:
- The companies collaborated to commercialise three insulin biosimilars i.e., insulin lispro and insulin aspart, and the long-acting insulin glargine in the US
- Meitheal’s parent company Nanjing King-Friend Biochemical Pharmaceutical will get an exclusive US marketing right to commercialize biosimilar versions of insulin aspart, insulin lispro, and insulin glargine upon the US FDA approval which is expected in 2026
- Additionally, Tonghua Dongbao and Nanjing King-Friend Biochemical will lead the development and supply of all three insulin biosimilars while all three companies will also share the royalties from the US sales
Ref: Businesswire | Image: Meitheal
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
